| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | |
| Research and development | 2,205 | 3,298 | 2,364 | |
| General and administrative | 2,708 | 3,623 | 3,097 | |
| Total operating expenses | 4,913 | 6,921 | 5,461 | |
| Interest (expense) income | -212 | -110 | -84 | |
| Foreign exchange loss | 2 | -12 | 2 | |
| Total other (expense) income | -210 | -122 | -82 | |
| Net loss and comprehensive loss | -5,123 | -7,043 | -5,543 | |
| Unrealized loss on available-for-sale securities | - | 0 | - | |
| Total comprehensive loss | - | -7,043 | -5,543 | |
| Earnings per share, diluted | -2.01 | -2.76 | -2.61 | |
| Net loss per share - basic | -2.01 | -2.76 | -2.61 | |
| Weighted-average common shares - basic | 2,552,429 | 2,552,429 | 2,126,287 | |
| Weighted-average common shares - diluted | 2,552,429 | 2,552,429 | 2,126,287 | |
Aptose Biosciences Inc. (APTOF)
Aptose Biosciences Inc. (APTOF)